News and blogs
385 results found.
Our Blood Cancer Action Plan to tackle blood cancer survival in the UK
Blood Cancer UK releases its comprehensive Action Plan "Taking blood cancer out of the shadows: A plan to increase survival in the UK"
Wales lags behind England in blood cancer survival
Our press release on our Blood Cancer Action Plan reveals how Wales is lagging behind England when it comes to blood cancer survival. Our landmark report is available to download in English and Welsh.
Ellie's blood cancer story
Ellie lived with acute myeloid leukaemia (AML). Her family are encouraging people to donate towards life-saving research.
Take at home tablet approved for blood cancer on NHS England
Zanubrutinib, is now available on the NHS in England for those with a type of blood cancer called marginal zone lymphoma.,
Drug, dasatinib approved for use on the NHS in Scotland
Dasatinib, is now approved for the treatment of adults with a form of leukaemia - Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) - on the NHS in Scotland.
New class of drug approved for myeloma in England and Wales
The very first bispecific drug for myeloma, elranatamab has been approved for restricted use in England and Wales as a fourth-line treatment.
New blood test for myeloma being researched at Birmingham
Two doctors at the University of Birmingham are developing a new technique to help diagnose and monitor people with the blood cancer, non-measurable myeloma.
Scotland approves two new blood cancer drugs
Two new drugs for the blood cancer, diffuse large B-cell lymphoma DLBCL have been made available for use on the NHS in Scotland as a third-line treatment.
Blood cancer treatment for a form of acute myeloid leukaemia approved for use on NHS
New blood cancer treatment for acute myeloid leukaemia (AML) with IDH1 mutation. The National Institute for Health and Care Excellence (NICE) approved Ivosidenib (Tibsovo) with azacitidine has made it available to those in England and Wales.
COVID-19 vaccines and blood cancer latest evidence
Lots of information continues to circulate about COVID-19 and vaccinations for immunocompromised people. Here's the latest evidence.
An update on Blood Cancer UK's strategy to beat blood cancer
One year after we launched our strategy to beat blood cancer, we look at how we're performing.
Prime Minister recognises blood cancer fundraiser
James Badger, from Harrogate who is raising £300,000 for Blood Cancer UK after his wife passed away from leukaemia has received Prime Minister Rishi Sunak’s Points of Light award.
Snowman author leaves gift to Blood Cancer UK
Blood Cancer UK are one of three charities left a gift in the Will of the author and illustrator Raymond Briggs, CBE.
Selinexor recommended in draft final guidance for myeloma
The drug, selinexor has been recommended by NICE in final draft guidance for use in people with myeloma if previous treatment has failed.
Minreet's marathon for mum with myeloma
Minreet and the Skipping Sikh will run the London Marathon for Blood Cancer UK to give hope to their mum who is receiving treatment for the blood cancer, myeloma
CAR-T therapy Kymriah available for a form of childhood and young-adult leukaemia on the NHS
'Life-changing' blood cancer drug, Kymriah is now available routinely on the NHS for childhood and young-adult B-cell acute lymphoblastic leukaemia on the NHS
How a Yorkshire house led to five pioneering research projects
Last year you raised an incredible £1.95m for Blood Cancer UK in the Omaze Millon Pound House Draw. Find out more about the incredible research projects this is helping to support.
Simon Thomas launches new blood cancer projects
Blood Cancer UK reveals that the money from their latest partnership with Omaze UK is their largest single donation to date. The money has now been invested into research via the Omaze x Blood Cancer UK Research Fund.
Louis Walsh's blood cancer
Walsh has a rare form of blood cancer, which affects the plasma cells in the blood.
Scotland drug regulators rule blood cancer isn't cost effective
Yescarta, the blood cancer drug is not to be made available on the NHS in Scotland even though it is in England. Blood Cancer UK says it highlights the inequality in access to blood cancer drugs across the UK.
